Artivion Management

Management criteria checks 4/4

Artivion's CEO is Pat Mackin, appointed in Sep 2014, has a tenure of 9.58 years. total yearly compensation is $3.18M, comprised of 24.4% salary and 75.6% bonuses, including company stock and options. directly owns 1.6% of the company’s shares, worth $13.84M. The average tenure of the management team and the board of directors is 3.8 years and 7.5 years respectively.

Key information

Pat Mackin

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage	24.4%
CEO tenure	9.6yrs
CEO ownership	1.6%
Management average tenure	3.8yrs
Board average tenure	7.5yrs

Recent management updates

Recent updates

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jan 13

Artivion Stock: A First Assessment

Dec 27

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Aug 04

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jun 27

Is Artivion (NYSE:AORT) Using Too Much Debt?

Mar 25

CryoLife (NYSE:CRY) Has A Somewhat Strained Balance Sheet

Dec 08

CryoLife, Inc. (NYSE:CRY) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 01

CryoLife (NYSE:CRY) Takes On Some Risk With Its Use Of Debt

Jul 30

CEO Compensation Analysis

How has Pat Mackin's remuneration changed compared to Artivion's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$3m	US$776k	-US$31m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$8m	US$750k	-US$19m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$5m	US$728k	-US$15m
Sep 30 2021	n/a	n/a	US$2m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$3m	US$606k	-US$17m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$6m	US$689k	US$2m
Sep 30 2019	n/a	n/a	US$2m
Jun 30 2019	n/a	n/a	US$3m
Mar 31 2019	n/a	n/a	US$709k
Dec 31 2018	US$3m	US$660k	-US$3m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$3m	US$640k	US$4m

Compensation vs Market: Pat's total compensation ($USD3.18M) is about average for companies of similar size in the US market ($USD3.43M).

Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.

CEO

Pat Mackin (56 yo)

9.6yrs

Tenure

US$3,176,413

Compensation

Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of Artivion, Inc. (formerly known as CryoLife, Inc.) since September 02, 2014 and has been its Chairman since...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Mackin	Chairman	9.6yrs	US$3.18m	1.6% $ 13.8m
Lance Berry	Executive VP of Finance	less than a year	US$1.64m	0.19% $ 1.6m
Amy Horton	VP & Chief Accounting Officer	17.7yrs	US$1.06m	0.33% $ 2.8m
Jean Holloway	Senior VP	9yrs	US$993.72k	0.39% $ 3.4m
John Davis	Senior VP & Chief Commercial Officer	less than a year	US$953.41k	0.38% $ 3.3m
Matthew Getz	VP of Human Resources & Chief Human Resources Officer	4.7yrs	no data	0.10% $ 904.7k
Marshall Stanton	Senior VP of Clinical Research & Chief Medical Officer	3.1yrs	US$1.61m	0.20% $ 1.7m
Robert Thomson	Vice President of Research & Development	less than a year	no data	0.032% $ 276.2k
Florian Tyrs	Vice President of Global Operations	3.8yrs	no data	0.062% $ 533.8k

3.8yrs

Average Tenure

55yo

Average Age

Experienced Management: AORT's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
James Mackin	Chairman	9.5yrs	US$3.18m	1.6% $ 13.8m
James Bullock	Independent Director	7.5yrs	US$217.50k	0.13% $ 1.2m
Thomas Ackerman	Independent Director	20.3yrs	US$230.00k	0.33% $ 2.9m
Anthony Semedo	Independent Director	2.5yrs	US$217.50k	0.090% $ 780.9k
Daniel Bevevino	Independent Director	20.3yrs	US$235.00k	0.33% $ 2.9m
Jeffrey Burbank	Independent Presiding Director	6.6yrs	US$265.00k	0.099% $ 855.7k
Jon Salveson	Independent Director	11.9yrs	US$215.00k	0.28% $ 2.4m
Marna Borgstrom	Independent Director	5.8yrs	US$220.00k	0.087% $ 758.0k
Elizabeth Hoff	Independent Director	1.5yrs	US$210.00k	0.045% $ 390.1k

7.5yrs

Average Tenure

63yo

Average Age

Experienced Board: AORT's board of directors are considered experienced (7.5 years average tenure).

Artivion Management

Management criteria checks 4/4

Key information

Recent management updates

Artivion, Inc., Annual General Meeting, May 14, 2024

Chairman recently sold US$262k worth of stock

Chairman recently sold US$242k worth of stock

Chairman notifies of intention to sell stock

Senior VP notifies of intention to sell stock

VP & Chief Accounting Officer notifies of intention to sell stock

Recent updates

Artivion, Inc. to Report Q1, 2024 Results on May 06, 2024

Artivion, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Chairman recently sold US$262k worth of stock

Chairman recently sold US$242k worth of stock

Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 880%

Price target increased by 11% to US$25.15

Artivion, Inc. Provides Earnings Guidance for the Year 2024

Artivion, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Artivion, Inc. announced that it expects to receive $350 million in funding

Is Artivion (NYSE:AORT) Using Too Much Debt?

Senior VP notifies of intention to sell stock

Artivion Stock: A First Assessment

VP & Chief Accounting Officer notifies of intention to sell stock

Artivion, Inc. Announces Chief Financial Officer Changes

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion, Inc. Announces Completion of Enrollment in PERSEVERE Trial

Consensus EPS estimates fall by 29%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. Revises Earnings Guidance for the Year 2023

Artivion, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Artivion, Inc. Announces Data from On-X Aortic Heart Valve Low INR Post-Market Study Presented in A Late-Breaking Science Session At the 37European Association for Cardio-Thoracic Surgery Annual Meeting

Artivion, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Senior Vice President of Operations recently sold US$248k worth of stock

Price target increased by 10% to US$24.90

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Chairman recently sold US$293k worth of stock

Artivion, Inc. Provides Earnings Outlook for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Insider exercised options to buy US$115k worth of stock.

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Artivion, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Price target decreased to US$23.13

Price target decreased to US$23.13

Artivion, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 profit in 3Q 2021)

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Artivion, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Artivion, Inc. Announces the Appointment of Elizabeth A. Hoff to Board of Directors

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Price target decreased to US$26.96

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

Insider recently sold US$125k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. Provides Financial Guidance for the Year 2022

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Artivion Initiates Enrollment in PERSEVERE Clinical Trial

Artivion, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Is Artivion (NYSE:AORT) Using Too Much Debt?

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$29.75

Insufficient new directors

Artivion, Inc. to Report Q1, 2022 Results on May 05, 2022

Artivion, Inc., Annual General Meeting, May 18, 2022

Is Artivion (NYSE:AORT) Using Too Much Debt?

Price target decreased to US$29.69

Full year 2021 earnings: EPS misses analyst expectations

Artivion Provides Revenue Guidance for the Full Year 2022